natgillin/translations-raw huggingface dataset:
Isolated cases reported in post-marketing experience.
Osamljeni primeri, o katerih so poročali v okviru izkušenj v obdobju trženja.
These compounds act at the same receptor system as memantine, and therefore adverse reactions (mainly central nervous system (CNS)-related) may be more frequent or more pronounced (see also section 4.5).
Te snovi delujejo na isti receptorski sistem kot memantin, zato so lahko neželeni učinki (zlasti s strani centralnega živčnega sistema (CŽS)) pogostejši in bolj izraženi (glejte tudi poglavje 4.5).
As the effects have neither been observed in long term studies in rodents nor in non-rodents, the clinical relevance of these findings is unknown.
Ker ti učinki niso bili opaženi v dolgotrajnih študijah pri glodalcih ali drugih živalih, je klinična pomembnost teh pojavov neznana.
If you go into hospital, let your doctor know that you are taking Marixino.
V primeru, da ste sprejeti v bolnišnico, obvestite zdravnika, da jemljete zdravilo Marixino.
Relative large overdoses (200 mg and 105 mg/day for 3 days, respectively) have been associated with either only symptoms of tiredness, weakness and/or diarrhoea or no symptoms.
Sorazmerno veliki preveliki odmerki (200 mg na dan oziroma 105 mg na dan, tri dni) so bili povezani bodisi samo s simptomi utrujenosti, šibkosti in/ali driske bodisi je bilo brez simptomov.
The most frequently occurring adverse reactions with a higher incidence in the memantine group than in the placebo group were dizziness (6.3 % vs 5.6 %, respectively), headache (5.2 % vs 3.9 %), constipation (4.6 % vs 2.6 %), somnolence (3.4 % vs 2.2 %) and hypertension (4.1 % vs 2.8 %).
Najpogostejši neželeni učinki, ki so se pogosteje pojavili pri skupini bolnikov, ki je jemala memantin, kot pri skupini, ki je prejemala placebo, so bili omotica (6,3 % proti 5,6 %), glavobol (5,2 % proti 3,9 %), zaprtje (4,6 % proti 2,6 %), zaspanost (3,4 % proti 2,2 %) in hipertenzija (4,1 % proti 2,8 %).
If you suffer from renal impairment (kidney problems), your doctor should closely monitor your kidney function and if necessary adapt the memantine doses accordingly.
V primeru, da imate ledvično okvaro (težave z ledvicami), naj vaš zdravnik skrbno nadzira delovanje ledvic in po potrebi ustrezno prilagodi odmerke memantina.
TAD Pharma GmbH Heinz-Lohmann-Straße 5 27472 Cuxhaven GERMANY
TAD Pharma GmbH Heinz-Lohmann-Straße 5 27472 Cuxhaven NEMČIJA
If tolerated well after at least 7 days of treatment, the dose could be increased up to 20 mg/day according to standard titration scheme.
Če bolnik zdravljenje dobro prenaša, se lahko odmerek po najmanj sedmih dneh zdravljenja zviša do 20 mg na dan, po standardni titracijski shemi.
Caution is recommended in patients with epilepsy, former history of convulsions or patients with predisposing factors for epilepsy.
Previdnost se priporoča pri bolnikih z epilepsijo, s konvulzijami v anamnezi ali pri bolnikih, ki so nagnjeni k epilepsiji.
What Marixino is and what it is used for
Kaj je zdravilo Marixino in za kaj ga uporabljamo
The renal elimination rate of memantine under alkaline urine conditions may be reduced by a factor of 7 to 9 (see section 4.4).
V primeru alkalnega urina lahko pride do zmanjšane hitrosti izločanja memantina za faktor 7- do 9 (glejte poglavje 4.4).
Other medicines and Marixino
Druga zdravila in zdravilo Marixino
Not known (frequency cannot be estimated from the available data): - Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti): Vnetje trebušne slinavke, vnetje jeter (hepatitis) in psihotične reakcije
Memantine is eliminated in a monoexponential manner with a terminal t½ of 60 to 100 hours.
Memantin se izloča na monoekspotencialni način s končnim razpolovnim časom (t1/2) 60 do 100 ur.
Marixino belongs to a group of medicines called NMDA-receptor antagonists.
Zdravilo Marixino spada v skupino zdravil, ki se imenujejo antagonisti receptorjev NMDA.
Studies in volunteers have demonstrated linear pharmacokinetics in the dose range of 10 to 40 mg.
Študije na zdravih prostovoljcih so pokazale, da ima memantin linearno farmakokinetiko v razponu odmerkov od 10 do 40 mg.
The brain contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve signals important in learning and memory.
V možganih se nahajajo tako imenovani receptorji N-metil-D-aspartata (NMDA), ki sodelujejo v prenosu živčnih signalov, ki so pomembni za učenje in spomin.
Treatment of adult patients with moderate to severe Alzheimer's disease.
Zdravljenje odraslih bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Excipient(s) with known effect:
Pomožna snov z znanim učinkom:
In volunteers with normal kidney function, total clearance (Cltot) amounts to 170 ml/min/1.73 m2 and part of total renal clearance is achieved by tubular secretion.
Pri prostovoljcih z normalnim delovanjem ledvic je celoten očistek (Cltot) 170 ml/min/1,73 m2; del celotnega ledvičnega očistka je dosežen s pomočjo tubularne sekrecije.
- Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
- Ostale učinkovine, kot so cimetidin, ranitidin, prokainamid, kinidin, kinin in nikotin, ki uporabljajo isti ledvični kationski transportni sistem kot amantadin, prav tako lahko vstopajo v interakcijo z memantinom, kar lahko vodi v tveganje za zvišane plazemske vrednosti.
If you take more Marixino than you should - In general, taking too much Marixino should not result in any harm to you.
Če ste vzeli večji odmerek zdravila Marixino, kot bi smeli - Na splošno zaužitje večjega odmerka zdravila Marixino ne sme imeti škodljivih posledic.
Specific ophthalmoscopic examinations in clinical studies with memantine did not disclose any ocular changes.
Specifične oftalmoskopske preiskave v kliničnih raziskavah z memantinom niso razkrile sprememb na očeh.
In the most extreme case of overdose, the patient survived the oral intake of a total of 2000 mg memantine with effects on the central nervous system (coma for 10 days, and later diplopia and agitation).
V najhujšem primeru prevelikega odmerka je bolnik preživel peroralni vnos 2000 mg memantina z.učinki na centralni živčni sistem (desetdnevna koma, kasneje diplopija in vznemirjenost).
Pharmacotherapeutic group: Psychoanaleptics, other anti-dementia drugs, ATC code: N06DX01.
Farmakoterapevtska skupina: psihoanaleptiki, druga zdravila za zdravljenje demence, oznaka ATC: N06DX01.
Due to the pharmacological effects and the mechanism of action of memantine the following interactions may occur: - The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine.
Glede na farmakološke učinke in mehanizem delovanja memantina se lahko pojavijo naslednje interakcije: - Na podlagi mehanizma delovanja se pričakuje, da se učinki L-dope, dopaminergičnih agonistov in antiholinergikov lahko okrepijo ob sočasnem zdravljenju z antagonisti NMDA kot je memantin.
The 10 mg film-coated tablet can be divided into equal doses.
10-miligramska filmsko obložena tableta se lahko deli na enaka odmerka.
What you need to know before you take Marixino
Kaj morate vedeti, preden boste vzeli zdravilo Marixino
- Concomitant use of memantine and amantadine should be avoided, owing to the risk of pharmacotoxic psychosis.
- Sočasni uporabi memantina in amantadina se je potrebno izogniti, ker lahko pride do pojava farmakotoksične psihoze.
- There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT.
- Obstaja možnost zmanjšane serumske koncentracije hidroklorotiazida (HCT) ob sočasni uporabi memantina in HCT oziroma kakršnikoli kombinaciji s HCT.
- In post-marketing experience, isolated cases with international normalized ratio (INR) increases have been reported in patients concomitantly treated with warfarin.
- V okviru izkušenj v obdobju trženja so poročali o osamljenih primerih povečanja mednarodnega umerjenega razmerja (INR) pri bolnikih, ki so bili sočasno zdravljeni z varfarinom.
This effect is known from other active substances with cationic amphiphilic properties.
Ta učinek je poznan pri učinkovinah s kationskimi amfifilnimi lastnostmi.
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (two 10 mg film-coated tablets or one 20 mg film-coated tablet once a day) as described above.
Na podlagi kliničnih študij je priporočen odmerek za bolnike nad,65 let starosti, 20 mg na dan (dve 10-miligramski filmsko obloženi tableti ali eno 20-miligramsko filmsko obloženo tableto enkrat na dan), kot je opisano zgoraj.
In patients with mild or moderate hepatic impaired function (Child-Pugh A and Child-Pugh B), no dose adjustment is needed.
Pri bolnikih z blago ali zmerno jetrno okvaro (Child-Pugh A in Child-Pugh B) prilagoditev odmerka ni potrebna.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before talking this medicinal product.
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte z zdravnikom.
Moderate to severe Alzheimer's disease usually causes impairment of driving performance and compromises the ability to use machinery.
Zmerna do huda Alzheimerjeva bolezen je običajno sama vzrok za nesposobnost vožnje in upravljanja strojev.
Memantine was not teratogenic in rats and rabbits, even at maternally toxic doses, and no adverse effects of memantine were noted on fertility.
Memantin ni bil teratogen pri podganah in kuncih, tudi pri odmerkih, toksičnih za mater, prav tako pa niso opazili neželenih učinkov na rodnost.
In short term studies in rats, memantine like other NMDA-antagonists have induced neuronal vacuolisation and necrosis (Olney lesions) only after doses leading to very high peak serum concentrations.
V kratkotrajnih študijah na podganah je memantin, tako kot drugi antagonisti receptorjev NMDA, povzročil nastanek vakuol in nekrozo v nevronih (Olneyeve lezije), vendar le pri odmerkih, ki dajo zelo visoko maksimalno plazemsko koncentracijo.
No data on the use of memantine in patients with severe hepatic impairment are available.
Podatkov o uporabi memantina pri bolnikih s hudo okvaro jeter ni na voljo.
At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 μmol in human frontal cortex.
Pri odmerku 20 mg memantina na dan so vrednosti v CSL skladne s ki vrednostjo (ki = konstanta inhibicije) memantina, ki je 0,5 µmol v frontalnem korteksu pri človeku.
Furthermore, Marixino has minor to moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care.
Tudi zdravilo Marixino lahko ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja strojev, zato je potrebno bolnike opozoriti na posebno previdnost.
When daily doses of 5 to 30 mg were administered, a mean cerebrospinal fluid (CSF)/serum ratio of 0.52 was calculated.
Ob dnevnih odmerkih od 5 do 30 mg so izračunali razmerje cerebrospinalni likvor (CSL)/serum 0,52.
Blister (PVC/PVDC-Alu foil): 14, 28, 30, 42, 50, 56, 60, 70, 84, 90, 98, 100 and 112 film-coated tablets, in a carton box.
Pretisni omot (PVC/PVDC//Al): 14, 28, 30, 42, 50, 56, 60, 70, 84, 90, 98, 100 ali 112 filmsko obloženih tablet, v škatli.
Talk to your doctor or pharmacist before taking Marixino: - if you have a history of epileptic seizures - if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure).
Pred začetkom jemanja zdravila Marixino se posvetujte z zdravnikom ali farmacevtom: - če ste v preteklosti imeli epileptične napade, - če ste pred kratkim preboleli srčni infarkt (srčna kap), imate kongestivno srčno popuščanje ali neurejeno hipertenzijo (visok krvni tlak).
In particular, Marixino may change the effects of the following medicines and their dose may need to be adjusted by your doctor: - amantadine, ketamine, dextromethorphan - dantrolene, baclofen - cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine - hydrochlorothiazide (or any combination with hydrochlorothiazide) - anticholinergics (substances generally used to treat movement disorders or intestinal cramps) - anticonvulsants (substances used to prevent and relieve seizures) - barbiturates (substances generally used to induce sleep) - dopaminergic agonists (substances such as L-dopa, bromocriptine) - neuroleptics (substances used in the treatment of mental disorders) - oral anticoagulants
Posebno v primeru, da skupaj z zdravilom Marixino jemljete naslednja zdravila, se lahko učinki le teh spremenijo in bo morda zdravnik moral prilagoditi odmerek: - amantadin, ketamin, dekstrometorfan - dantrolen, baklofen - cimetidin, ranitidin, prokainamid, kinidin, kinin, nikotin - hidroklorotiazid (ali kombinacije zdravil, ki vsebujejo hidroklorotiazid) - antiholinergiki (zdravila, ki se običajno uporabljajo za zdravljenje motenj gibanja in trebušnih krčev) - antikonvulzivi (zdravila za preprečevanje ali lajšanje epileptičnih krčev) - barbiturati (zdravila, ki se običajno uporabljajo kot uspavala) - dopaminergični agonisti (učinkovine kot L-dopa, bromokriptin) - nevroleptiki (zdravila za zdravljenje duševnih motenj) - peroralni antikoagulanti.
Thereafter, the clinical benefit of memantine and the patient's tolerance of treatment should be reassessed on a regular basis according to current clinical guidelines.
Potem je potrebno ocenjevati klinično korist in prenašanje zdravljenja z memantinom v skladu s trenutno veljavnimi kliničnimi smernicami.
Maintenance dose The recommended maintenance dose is 20 mg per day.
Vzdrževalni odmerek Priporočeni vzdrževalni odmerek je 20 mg na dan.
Marixino is used for the treatment of patients with moderate to severe Alzheimer's disease.
Zdravilo Marixino uporabljamo za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
See section 2 "Marixino contains lactose".
Glejte poglavje 2 "Zdravilo Marixino vsebuje laktozo".
Very Rare (may affect up to 1 in 10,000 people): - Seizures.
Zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): Epileptični napadi
Therapy should only be started if a caregiver is available who will regularly monitor the intake of the medicinal product by the patient.
Zdravljenje naj se začne le v primeru, če je na voljo ustrezna oseba, ki za bolnika skrbi in ki lahko nadzoruje bolnikovo redno jemanje zdravila.
A meta-analysis of patients with moderate to severe Alzheimer's disease (MMSE total scores < 20) from the six phase III, placebo-controlled, 6-month studies (including monotherapy studies and studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains.
Meta-analiza bolnikov z zmerno do hudo Alzheimerjevo boleznijo (skupna ocena KPSS ob vključitvi < 20), ki je zajela šest študij III. faze, kontroliranih s placebom in trajajočih šest mesecev (vključno s študijami zdravljenja v monoterapiji ter študij bolnikov na stabilnem odmerku inhibitorjev acetilholinesteraze), je pokazala statistično značilen učinek v korist zdravljenja z memantinom na področjih spoznavnih funkcij ter globalnih in funkcionalnih domen.
Pregnancy The use of memantine in pregnant women is not recommended.
Nosečnost Uporaba memantina med nosečnostjo ni priporočljiva.
Concomitant use of N-methyl-D-aspartate (NMDA)-antagonists such as amantadine, ketamine or dextromethorphan should be avoided.
Sočasni uporabi antagonistov N-metil-D-aspartata (NMDA), kot so amantadin, ketamin ali dekstrometorfan, se je potrebno izogniti.
The recommended maintenance dose is 20 mg once a day, which is reached at the beginning of the 4
Priporočeni vzdrževalni odmerek je 20 mg enkrat na dan, dosežete pa ga na začetku četrtega tedna zdravljenja.
Marixino acts on these NMDA-receptors improving the transmission of nerve signals and the memory.
Zdravilo Marixino deluje na receptorje NMDA in izboljša prenos živčnih signalov in spomin.
In clinical trials in mild to severe dementia, involving 1,784 patients treated with memantine and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with memantine did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity.
V kliničnih preskušanjih bolnikov z zmerno do hudo demenco, ki so zajeli 1784 bolnikov, zdravljenih z memantinom in 1595 bolnikov, ki so prejemali placebo, se skupna incidenca neželenih učinkov pri memantinu ni razlikovala od placeba, neželeni učinki pa so bili po resnosti večinoma blagi do zmerni.
Concomitant administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify their effects and a dose adjustment may be necessary.
Sočasno dajanje memantina in spazmolitikov, dantrolena ali baklofena, lahko spremeni njihove učinke, zato bo morda potrebno prilagoditi odmerke.
In post-marketing experience these reactions have been reported in patients treated with memantine.
V okviru izkušenj v obdobju trženja so te učinke navajali pri bolnikih, zdravljenih z memantinom.
The patient experienced central nervous system symptoms such as restlessness, psychosis, visual hallucinations, proconvulsiveness, somnolence, stupor, and unconsciousness.
Pojavili so se simptomi, povezani s centralnim živčnim sistemom, kot so: nemir, psihoza, vidne halucinacije, nagnjenost h konvulzijam, zaspanost, stupor in nezavest.
You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your doctor may need to adjust the dose of your medicine.
Obvestite zdravnika, če ste pred kratkim spremenili ali če nameravate bistveno spremeniti prehrano (npr. če preidete iz običajne prehrane na strogo vegetarijansko prehrano), ali če imate ledvično tubularno acidozo (preveliko količino kislih spojin v krvi zaradi renalne disfunkcije (slabega delovanja ledvic)) ali če ste zboleli zaradi hudega vnetja sečil (organski sistem po katerem se prenaša seč).
The patient should take two 10 mg film-coated tablets (20 mg) or one 20 mg film-coated tablet per day.
Bolnik mora jemati dve 10-miligramski filmsko obloženi tableti (20 mg) ali eno 20-miligramsko filmsko obloženo tableto na dan.
In a clinical study in young healthy subjects, no relevant effect of memantine on the pharmacokinetics of galantamine was observed.
V klinični raziskavi pri mladih zdravih posameznikih ni bilo opaziti pomembnega vpliva memantina na farmakokinetiko galantamina.
In the event of overdose, treatment should be symptomatic.
Pri prevelikem odmerku je potrebno simptomatično zdravljenje.
Renal handling also involves tubular reabsorption, probably mediated by cation transport proteins.
V ledvicah poteka tudi tubularna reabsorpcija, verjetno preko beljakovinskega kationskega transporta.
Marixino film-coated tablets are available in boxes of 14, 28, 30, 42, 50, 56, 60, 70, 84, 90, 98, 100 and 112 film-coated tablets in blisters.
Zdravilo Marixino je na voljo v škatlah po 14, 28, 30, 42, 50, 56, 60, 70, 84, 90, 98, 100 in 112 filmsko obloženih tablet v pretisnih omotih.
In this case, monitoring of your kidney function should be performed by your doctor at specified intervals.
V teh primerih bo zdravnik nadzoroval ledvično delovanje v določenih časovnih presledkih.
14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 42 film-coated tablets 50 film-coated tablets 56 film-coated tablets 60 film-coated tablets 70 film-coated tablets 84 film-coated tablets 90 film-coated tablets 98 film-coated tablets 100 film-coated tablets 112 film-coated tablets
14 filmsko obloženih tablet 28 filmsko obloženih tablet 30 filmsko obloženih tablet 42 filmsko obloženih tablet 50 filmsko obloženih tablet 56 filmsko obloženih tablet 60 filmsko obloženih tablet 70 filmsko obloženih tablet 84 filmsko obloženih tablet 90 filmsko obloženih tablet 98 filmsko obloženih tablet 100 filmsko obloženih tablet 112 filmsko obloženih tablet
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance-active substance interaction of memantine with glyburide/metformin or donepezil was observed.
V raziskavah farmakokinetike (PK) posameznega odmerka pri mladih zdravih osebah ni bilo opaziti interakcij učinkovina-učinkovina memantina z gliburidom/metforminom ali donepezilom.
Do not use this medicine after the expiry date which is stated on the blister and carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Ocular changes were inconsistently observed in repeat dose toxicity studies in rodents and dogs, but not in monkeys.
V študijah toksičnosti pri ponavljajočih odmerkih so pri glodalcih in psih, ne pa tudi pri opicah,
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer's disease assessment scale (ADAS-cog) (p = 0.003) and CIBIC-plus (p = 0.004) at week 24 (last observation carried forward (LOCF)).
Pri bolnikih, zdravljenih z memantinom, se je pokazal statistično značilno boljši učinek kot pri bolnikih, ki so prejemali placebo, pri primarnih ciljih študije: Lestvica za ocenjevanje Alzheimerjeve bolezni (Alzheimer´s disease assessment scale ali,ADAS-cog) (p = 0,003) in CIBIC-plus (p = 0,004) po 24 tednih (last observation carried forward (LOCF)).
Main human metabolites are N-3,5-dimethyl-gludantan, the isomeric mixture of 4- and 6-hydroxymemantine, and 1-nitroso-3,5-dimethyl-adamantane.
Pri človeku so poglavitni metaboliti N-3,5-dimetil-gludantan, izomerna mešanica 4- in 6-hidroksi-memantina in 1-nitrozo-3,5-dimetiladamantana.
Your doctor will tell you whether your illness allows you to drive and to use machines safely.
Vpliv na sposobnost upravljanja vozil in strojev Zdravnik vam bo povedal, ali kljub vaši bolezni lahko varno vozite in varno upravljate strojev.
Breast-feeding Women taking Marixino should not breast-feed.
Dojenje Ženske, ki jemljejo zdravilo Marixino, ne smejo dojiti.
The usual starting dose is half a tablet once a day (1 x 5 mg) for the first week.
Običajni začetni odmerek je polovica tablete enkrat na dan (1 x 5 mg) v prvem tednu.
In order to reduce the risk of undesirable effects, the maintenance dose is achieved by upward titration of 5 mg per week over the first 3 weeks as follows:
Največji dnevni odmerek je 20 mg na dan. Da bi zmanjšali pojavnost neželenih učinkov, je potrebno postopno zviševanje odmerka po 5 mg na teden v prvih treh tednih zdravljenja, kot sledi:
The use of medicinal products called amantadine (for the treatment of Parkinson's disease), ketamine (a substance generally used as an anaesthetic), dextromethorphan (generally used to treat cough) and other NMDA-antagonists at the same time should be avoided.
Potrebno se je izogibati sočasni uporabi zdravil, kot so amantadin (za zdravljenje Parkinsonove bolezni), ketamin (učinkovina, ki se običajno uporablja kot anestetik), dekstrometorfan (običajno se uporablja za zdravljenje kašlja) in ostali zaviralci receptorjev NMDA.
Women taking memantine should not breast-feed.
Ženske, ki jemljejo memantin, naj ne dojijo.